A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
Effects of prostacyclin analogous iloprost trometamol on bleomisin induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010
Protective effect of leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 669s Year: 2006
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
Effect of thromboxane A2 (TXA2 ) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Inhibition by roflumilast vs cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Naftopidil, a selective a1 adrenoceptor antagonist, inhibits the growth of lung fibroblasts and attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
Esterification of iloprost enhances its protective effects on pulmonary endothelium Source: Respiratory Failure and Mechanical Ventilation Conference 2020 Year: 2020
Inhibitory effect of PGE2 receptor subtype, EP4, in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007
Effects of the NO donor molsidomine on prostacyclin synthase gene expression in rats with chronic hypoxic pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 414s Year: 2001
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
Effects of acute nitric oxide synthase inhibition in a model of chronic airway inflammation in guinea pigs: correlation with capsaicin pretreatment Source: Eur Respir J 2002; 20: Suppl. 38, 383s Year: 2002
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Anti-inflammatory activity of doxofylline and theophylline in LPS-induced lung inflammation Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012
Effects of a leukotriene B4 receptor antagonist on bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2009; 34: 1444-1451 Year: 2009
A role of prostaglandin D2 receptor, CRTH2, on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Understanding allergic airway inflammation with the help of animal models Year: 2008
Abrogation of bleomycin induced inflammation and lung fibrosis by angiotensin AT1 receptor antagonist. Relevance of PGE-2 modulation Source: Eur Respir J 2005; 26: Suppl. 49, 82s Year: 2005
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007